Comparison of fluorine-18/copper-64-labeled DOTATATE and 68Ga-DOTATATE in PET imaging of neuroendocrine tumor

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300072266

Enrollment

Unknown

Registered

2023-06-08

Start date

2023-06-07

Completion date

Unknown

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuroendocrine tumor

Interventions

Gold Standard:Primary site: biopsy pathology or postoperative pathology Metastasis: confirmed by pathology or follow-up

Index test:The number of lesions and different PET metabolic parameters (SUVmax, etc.) in the area of interest were compared between the total body PET/CT of all patients.

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria 1 Voluntary subjects, patients or their legal representatives signed informed consent; 2 Age > 18 years and < 85 years; 3 Routine image examination prompts NET; 4 Patients who plan to undergo puncture biopsy in our hospital to obtain pathological results (type, location, etc.).

Exclusion criteria

Exclusion criteria: Exclusion criteria ? Patients who could not tolerate PET/CT examination; ? Patients who plan to undergo puncture biopsy between tests.

Design outcomes

Primary

Measure	Time frame
SUVmax;	—

Countries

China

Contacts

Public ContactJinming Zhang

Department of Nuclear Medicine, First Medical Center, PLA General Hospital

zhangjm301@163.com+86 138 0121 0291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026